ABSTRACT
Neutralizing monoclonal antibodies against dengue virus cross-react with other flaviviruses due to the sequence homology between them, such as the antibodies targeting envelope protein and non-structural protein 1. Apart from exerting protective effects in infected animals, cross-neutralizing antibodies could also cause antibody-dependent enhancement (ADE) in vivo. This review summarized the progress in cross-reactivity of neutralizing antibodies against dengue virus.
ABSTRACT
West Nile virus(WNV)is a member of the Flavivirus genus, which can cause zoonotic diseases or even death. With the gradual globalization of WNV infection epidemic, there exists an input risk in China. Now there are no approved vaccines and drugs for the prevention and treatment of human infection with WNV. Hence, research and de- velopment of drugs against WNV is necessary. WNV envelope(E)protein, the main antigen of neutralizing antibody, is involving in the infection of the target cells by the virus. The E protein contains three structural domains(D, DⅡ and DIII). This review briefly describes the recent advances in neutralizing antibodies targeting these three domains.